
Novo Holdings A/s
About Novo Holdings A/s’s 13F portfolio
Novo Holdings A/s is an institutional investment manager that discloses its US-listed holdings each quarter through an SEC Form 13F filing. As of , Novo Holdings A/s reported $1.7B across 25 US-listed positions (). Its largest position is EDGEWISE THERAPEUTICS INC (EWTX) at 13% of the reported book, and its ten biggest holdings make up 73% of the portfolio. Browse every manager in the fund managers directory, or see the legendary investors we track on the superinvestors page.
| # | Stock | Price | % of portfolio | Shares | Value |
|---|---|---|---|---|---|
| 1 | NASDAQ: EWTX EDGEWISE THERAPEUTICS INC | $41.17 −0.48% | 13% | 5.3M | $217.4M |
| 2 | NASDAQ: ASML ASML HOLDING N V | $1,356.20 −2.80% | 11% | 95K | $188.9M |
| 3 | NASDAQ: COAG HEMAB THERAPEUTICS HLDGS INC | — — | 8.9% | 4.2M | $153.6M |
| 4 | NYSE: BN BROOKFIELD CORP | $38.94 −1.14% | 8.7% | 3.5M | $149.5M |
| 5 | NASDAQ: MPLT MAPLIGHT THERAPEUTICS INC | $6.42 −3.46% | 7.7% | 3.7M | $132.1M |
| 6 | NASDAQ: MIRM MIRUM PHARMACEUTICALS INC | $95.51 +3.27% | 7.6% | 1.1M | $131.7M |
| 7 | NASDAQ: AVLN AVALYN PHARMACEUTICALS INC | — — | 7.4% | 3.9M | $127.8M |
| 8 | NYSE: CRM SALESFORCE INC | $183.31 −3.72% | 3.6% | 393K | $61.6M |
| 9 | NASDAQ: AVBP ARRIVENT BIOPHARMA INC | $11.26 +3.30% | 3.0% | 1.5M | $52.1M |
| 10 | NASDAQ: ELVN ENLIVEN THERAPEUTICS INC | $46.41 +3.39% | 2.9% | 1.0M | $50.8M |
| 11 | NASDAQ: CRNX CRINETICS PHARMACEUTICALS IN | $84.95 0.00% | 2.9% | 1.3M | $49.4M |
| 12 | NASDAQ: PHVS PHARVARIS N V | $31.66 +0.35% | 2.8% | 1.4M | $48.4M |
| 13 | NYSE: FND FLOOR & DECOR HLDGS INC | $46.38 −3.48% | 2.7% | 797K | $47.3M |
| 14 | NASDAQ: PCVX VAXCYTE INC | $58.36 −0.27% | 2.7% | 800K | $46.5M |
| 15 | NASDAQ: FDMT 4D MOLECULAR THERAPEUTICS IN | $10.72 +2.49% | 2.5% | 3.2M | $43.2M |
| 16 | NASDAQ: VRDN VIRIDIAN THERAPEUTICS INC | $31.44 +4.38% | 2.3% | 2.1M | $39.2M |
| 17 | NASDAQ: CLDX CELLDEX THERAPEUTICS INC NEW | $27.96 +1.49% | 2.2% | 1.0M | $38.1M |
| 18 | NASDAQ: ALMS ALUMIS INC | $4.33 −1.48% | 1.8% | 1.1M | $31.0M |
| 19 | NASDAQ: XENE XENON PHARMACEUTICALS INC | $37.56 −0.50% | 1.7% | 485K | $29.3M |
| 20 | NYSE: BABA ALIBABA GROUP HLDG LTD | $83.31 −1.26% | 1.4% | 257K | $24.7M |
| 21 | NASDAQ: DYN DYNE THERAPEUTICS INC | $16.03 +1.01% | 1.2% | 960K | $21.3M |
| 22 | NASDAQ: BBOT BRIDGEBIO ONCOLOGY THERAPEUT | $1.86 +3.05% | 1.0% | 2.3M | $17.1M |
| 23 | NASDAQ: INSM INSMED INC | $144.46 +20.58% | 0.7% | 121K | $12.9M |
| 24 | NASDAQ: MQ MARQETA INC | $16.43 −1.68% | 0.4% | 442K | $7.2M |
| 25 | NASDAQ: LNZA LANZATECH GLOBAL INC | $2.98 +1.02% | 0.1% | 158K | $1.1M |
Showing the 25 largest positions reported in this 13F.
- Healthcare56%
- Technology15%
- Financial Services8.7%
- Consumer Cyclical4.2%
- Industrials0.1%
- NewCOAGHEMAB THERAPEUTICS HLDGS INC—$153.6M
- NewAVLNAVALYN PHARMACEUTICALS INC—$127.8M
- NewFNDFLOOR & DECOR HLDGS INC—$47.3M
- AddedVRDNVIRIDIAN THERAPEUTICS INC+6.8%$39.2M
- NewALMSALUMIS INC—$31.0M
- NewDYNDYNE THERAPEUTICS INC—$21.3M
- AddedBBOTBRIDGEBIO ONCOLOGY THERAPEUT+2.9%$17.1M
- NewINSMINSMED INC—$12.9M
- ReducedMIRMMIRUM PHARMACEUTICALS INC−15.1%$131.7M
- ReducedAVBPARRIVENT BIOPHARMA INC−22.8%$52.1M
- ReducedELVNENLIVEN THERAPEUTICS INC−21.9%$50.8M
- ReducedCRNXCRINETICS PHARMACEUTICALS IN−14.8%$49.4M
- ReducedPHVSPHARVARIS N V−20.0%$48.4M
- ReducedPCVXVAXCYTE INC−7.0%$46.5M
- ReducedFDMT4D MOLECULAR THERAPEUTICS IN−11.0%$43.2M
- ReducedCLDXCELLDEX THERAPEUTICS INC NEW−14.6%$38.1M
- SoldBMRNBIOMARIN PHARMACEUTICAL INC−100%—
- SoldAPGEAPOGEE THERAPEUTICS INC−100%—
Companies where this manager has disclosed a stake of more than 5% of a class of shares, as reported to the SEC on Schedule 13D (activist) or 13G (passive). Figures are as disclosed in each filing — tap a date to open the source document.
| # | Stock | Type | % of class | Shares | Filed |
|---|---|---|---|---|---|
| 1 | COAG Hemab Therapeutics Holdings, Inc. | 13G | 9.0% | 4.2M | Filed 14 AUG 2026 |
| 2 | AVLN Avalyn Pharma Inc. | 13G | 8.8% | 3.9M | Filed 14 AUG 2026 |
| 3 | MPLT MAPLIGHT THERAPEUTICS, INC. | 13D | 8.4% | 3.7M | Filed 04 NOV 2025 |
| 4 | FDMT 4D MOLECULAR THERAPEUTICS, INC. | 13G | 6.4% · 2 classes | 3.7M | Filed 17 FEB 2026 |
| 5 | OBX Obsidian Therapeutics, Inc. | 13G | 5.1% | 3.1M | Filed 10 AUG 2026 |
Showing all 5 disclosed stakes.
Reading Novo Holdings A/s’s 13F portfolio
Novo Holdings A/s’s $1.7B 13F book is spread across 25 reported positions and is highly concentrated — its ten largest positions alone are 73% of the portfolio. A book this concentrated means a small group of names drives most of its performance. Its five largest positions are EWTX, ASML, COAG, BN and MPLT, led by EDGEWISE THERAPEUTICS INC (EWTX) at 13% of the portfolio. The heaviest sector exposure is Healthcare (56%), then Technology (15%).
What Novo Holdings A/s changed last quarter
Between 2026-03-31 and Q2 2026, Novo Holdings A/s was a net seller: it opened 6 new positions and added to 2 more, while trimming 8 and closing 3 outright. Against a 25-name book, that is high turnover, pointing to an active reshuffle of the book. Its largest new or increased position was HEMAB THERAPEUTICS HLDGS INC (COAG), and its biggest reduction was MIRUM PHARMACEUTICALS INC (MIRM).
What a 13F does and doesn’t reveal
A 13F captures only Novo Holdings A/s’s long positions in US-listed stocks at a single quarter-end, so it is best read as a lagged snapshot rather than a live portfolio. It won’t show shorts, cash, bonds, or holdings listed outside the US, and it never reveals the price paid or the reasoning behind a trade. The signal is in the pattern over time: which names Novo Holdings A/s is building up, trimming, or exiting, and how concentrated the book stays from quarter to quarter.
Frequently asked questions
What is an SEC 13F filing?
A Form 13F is a report that every institutional investment manager with at least $100 million in US-listed securities must file with the SEC within 45 days of each quarter's end. It lists the manager's long positions in US-listed stocks and certain options, with the share count and market value of each. Novo Holdings A/s's profile on this page is built directly from those filings.
How current is the 13F data on Novo Holdings A/s's page?
It reflects Novo Holdings A/s's most recently filed 13F, currently the quarter ending Q2 2026. Because managers have up to 45 days after a quarter closes to file, a 13F is always a slightly lagged view rather than a live portfolio. When Novo Holdings A/s files its next quarterly report, this page refreshes automatically.
Can I see Novo Holdings A/s's complete list of holdings?
This page highlights Novo Holdings A/s's largest positions rather than all 25 names in the filing. The complete, position-by-position 13F is public and available from the SEC's EDGAR database under Novo Holdings A/s's filings.
Does a 13F show everything Novo Holdings A/s owns?
No. A 13F only covers long positions in US-listed stocks and certain options. It leaves out short positions, cash, bonds, commodities, foreign-listed stocks, and private holdings, so it is a partial view of Novo Holdings A/s's book rather than its full strategy or total assets.
Is 13F data investment advice?
No. Everything here is educational. 13F positions are disclosed with a delay, cover only long US-listed holdings, and never explain why Novo Holdings A/s made a trade or at what price. Treat it as a research lens, not a recommendation, and speak with a licensed financial advisor before making investment decisions.
Not investment advice. Holdings data comes from public SEC Form 13F filings, which are filed with a delay of up to 45 days and may be amended later. It describes historical, disclosed positions in US-listed securities only, meaning no shorts, cash, or foreign holdings, and it is not a recommendation. Always do your own research and speak with a licensed financial advisor before making investment decisions.

